Staphylococcus epidermidis Bacteria Reduction

Jessica Dobbin
WellAir Research & Development Laboratory, DCU ALPHA - Ireland
Full Report


To evaluate the efficacy of the Defend 400 at reducing aerosolized Staphylococcus epidermidis, a surrogate for Staphylococcus aureus, MRSA and Micrococcus luteus. MRSA is a known superbug.


The environmental chamber used for this study was 30m3 in size and designed to replicate a room setting.

The bio-aerosol was generated using a 24-jet Collison nebuliser operated with a purified filtered air supply.

The bio-aerosol samples were collected at 15-minute intervals in sterile SKC BioSampler impingers to determine the chamber concentration.

Summary of Results

The Defend 400 achieved greater than a log-4 reduction (>99.99%) of Staphylococcus epidermidis after 45 minutes.

Defend 400 achieved 99.99% reduction of MRSA surrogate

Contact Us

USA Headquarters
3540 Toringdon Way, Suite 200 Charlotte, NC  28277
1 866 508 1118

Ireland Headquarters
DCU Innovation Campus
Old Finglas Road
Glasnevin, Dublin D11 KXN4
+353 1 907 2750